A study of VY-SOD101 for a treatment of monogenic form of Amyotrophic lateral sclerosis (ALS)
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2017
At a glance
- Drugs VY SOD101 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- 01 Nov 2017 According to a Voyager Therapeutics media release, company plans to file IND in 2019.
- 20 May 2016 New trial record
- 12 May 2016 According to a Voyager Therapeutics media release, the company expects to file an Investigational New Drug (IND) application for VY-SOD101 in late 2017.